CAR-T and the growth of cell therapy trials

Cell therapies are revolutionizing the approach to oncology care. While CAR-T therapies are the dominant approach globally with development heavily favored in the US and China, TCR-T, CAR-NK and TIL therapy approaches are steadily rising. Contact Cerner Enviza to explore the cell therapy trial landscape, its evolution across solid/heme tumors, the novel targets being explored, and the developers moving forward with particular strategies.